Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer is a research paper published in Gynecologic Oncology Reports (2024). On theSindex it has a DataRank of 0.292. It has been cited 6 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →National Institutes of Health
Grant: 1U01CA176067-01A1
Integrated genomic analysis of racial disparities in endometrial cancer
National Institutes of Health
Grant: 2P30CA016359-15
COMPREHENSIVE CANCER CENTER
NCI NIH HHS
Grant: P30 CA016359
NCI NIH HHS
Grant: U01 CA176067
NCATS NIH HHS
Grant: UL1 TR001863
Fields of Study
Keywords
Sustainable Development Goals